evoke study semaglutide When GLP-1s become brain drugs EVOKE/EVOKE+ - Neuroprogressive and Dementia

This is rarely used for PCOS its a dose more commonly seen in heart failure or refractory edema

The science behind semaglutide stability testing For those who want to understand the deeper science, here is how pharmaceutical companies determine expiration dates for peptide medications

The finding that 88% of medications retained potency well beyond expiration dates does not apply to peptide drugs, which are inherently less stable than conventional small molecules

Patients report reduced cravings and smaller portion sizes, making it easier to stick to a healthier lifestyle

Holding at a dose for an extra 4 weeks before escalating is a medically supported strategy when: Nausea or vomiting persists beyond 2 weeks at the current dose You are unable to eat at least 1,000 calories per day comfortably Dehydration symptoms appear (dark urine, dizziness on standing, dry mouth) You are losing weight faster than 1 to 2 pounds per week on the current dose (aggressive weight loss increases side effect risk) In the STEP trials, delayed escalation did not compromise overall weight loss outcomes at 68 weeks